Rheumatoid arthritis three-month trials are adequate for signs and symptoms claim -- Pfizer.
RHEUMATOID ARTHRITIS DRUG THREE-MONTH TRIAL DURATION "REMAINS APPROPRIATE for evaluation of agents with a rapid onset of action," Pfizer maintains in Feb. 14 comments on FDA's draft guidance for industry development of RA drugs. "For agents with slower onset or potential for rapid loss of effect," Pfizer suggested, "a minimum of six months may be more appropriate" to gain a claim of reduction in signs and symptoms.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth